Quantcast

Boehringer Ingelheim’s asthma drug test shows good results

Boehringer Ingelheim has reported new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.

Two new analyses show SPIRIVA RESPIMAT improved lung function in children and adolescents with moderate to severe asthma, regardless of their allergic status, the company said.

The company further explained that in the post hoc analyses of several Phase III randomized, double-blind, placebo controlled studies in pediatric and adolescent patients with moderate to severe asthma, adding SPIRIVA RESPIMAT improved peak FEV1(0-3h) and trough FEV1 across a range of baseline immunoglobulin E (IgE) levels and eosinophil counts, compared to placebo. Adding SPIRIVA RESPIMAT also reduced the risk of exacerbations compared to placebo, in pediatric and adolescent patients, regardless of baseline IgE levels and blood eosinophil counts.

A separate subgroup analysis showed that adding SPIRIVA RESPIMAT was effective at reducing symptoms and improving lung function in adults with mild to severe asthma in all BMI categories, including those who were overweight or obese, a population that often experiences symptoms that are harder to control. The data showed that adding SPIRIVA RESPIMAT improved peak FEV1(0-3h) and trough FEV1 in adult patients with mild to severe asthma compared to placebo, regardless of their BMI.

Many people with asthma continue to live with uncontrolled symptoms. These new analyses show that adding SPIRIVA RESPIMAT to another maintenance treatment may improve breathing, even for people whose symptoms may be harder to control, such as those with higher body mass index or people who have both asthma and allergies,” said Danny McBryan, MD, Head of Clinical Development & Medical Affairs, COPD & Asthma, Boehringer Ingelheim Pharmaceuticals, Inc. “These analyses are examples of Boehringer Ingelheim’s commitment to scientific research that helps improve understanding of who may best benefit from our medicines.”

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.